Tretazicar (CB 1954), an antitumor prodrug, is highly selective against the Walker 256 rat tumour line. Tretazicar is enzymatically activated to generate a bifunctional agent, which can form DNA-DNA interstrand cross-links. Tretazicar in rat cells involve

Carbamazepine, a sodium channel blocker, is an anticonvulsant drug.

ZM306416 is a vascular endothelial growth factor receptor (VEGFR) antagonist.

ZM 336372 is a potent and selective c-Raf inhibitor with IC50 of 70 nM, 10-fold selectivity over B-RAF, no inhibition to PKA/B/C, AMPK, p70S6, etc.

ZM 241385 is a Potent A2 adenosine receptor antagonist, with approx 50-fold selectivity for A2A receptors.

ZCL278 is a Cdc42 small molecule modulator that directly binds to Cdc42 (Kd=11.4 uM) and inhibits Cdc42-intersectin interaction.

Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor.

Z3(NSC 42834), a novel specific inhibitor of Jak2, inhibits Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner but was not cytotoxic to cells at concentrations that inhibited kinase activity.

YS 49 inhibits Ang II-stimulated proliferation of VSMCs via induction of HO-1.

YM201636 is a selective PIKfyve inhibitor with IC50 of 33 nM, less potent to p110α.

YM155 is a potent IAP (inhibitor of apoptosis proteins) inhibitor for survivin with IC50 of 0.54 nM.

YM 90709 has been reported to be a selective inhibitor of interleukin-5 (IL-5).

YKL-06-061 is a potent and selective SIK (salt-inducible kinase) inhibitor.

YH239-EE, ethyl ester of the free carboxylic acid compound YH239, is a potent p53-MDM2 antagonizing and apoptosis-inducing agent

YF2 is a First-in-Class Histone Acetyltransferase (HAT) Activators for Precision Targeting of Epigenetic Derangements in Lymphoma.

YC-1(Lificiguat) is a soluble guanylyl cyclase(sGC) activator; binds to the heme-containing domain of the β subunit with Kd value of 0.6-1.1 μM in the presence of CO.

Y-320 is a new phenylpyrazoleanilide immunomodulator; inhibits IL-17 production by CD4 T cells stimulated with IL-15 with IC50 values of 20 to 60 nM.

Y-27632 2HCl is a selective ROCK1 (p160ROCK) inhibitor with Ki of 140 nM.

Y15 is a novel small molecule FAK phosphorylation inhibitor; specifically block phosphorylation of Y397-FAK and total phosphorylation of FAK.

XMD8-92 is highly selective ERK5/BMK1 inhibitor with Kd values of 80, 190, 600 and 890 nM for BMK1, DCAMKL2, PLK4 and TNK1 respectively ; displays selectivity over 402 diverse kinases.

XMD-17-51 is a potent NUAK1-specific NUAK1 inhibitor

XMD17-109 is a novel, specific ERK-5 inhibitor with an EC50 4.2 uM in HEK293 cells.

XL888 is an orally bioavailable, ATP-competitive, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity.

XL388 is a Novel Class of Highly Potent, Selective, ATP-Competitive, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin (mTOR).

XL228 is a protein kinase inhibitor targeting IGF1R, the Aurora kinases, FGFR1-3, ABL and SRC family kinases.

XL184 (Cabozantinib) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM, respectively.

XL147 analogue (SAR245408) is a selective and reversible class I PI3K inhibitor for wild type and mutant p110α with IC50 of 40 nM and 40 nM, respectively.

XL019 is an orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2) with potential antineoplastic activity.

Ximelagatran is an orally active direct thrombin inhibitor.

XCT-790 is a potent, selective and inverse agonist of estrogen-related receptor alpha(ERRα); induces cell death in chemotherapeutic resistant cancer cells.